Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 901437, 17 pages
http://dx.doi.org/10.1155/2014/901437
Research Article

The Protective Effect of Beraprost Sodium on Diabetic Cardiomyopathy through the Inhibition of the p38 MAPK Signaling Pathway in High-Fat-Induced SD Rats

Department of Endocrinology, Jinling Hospital, Medical School of Nanjing University, 305 East Zhongshan Road, Nanjing, Jiangsu 210002, China

Received 14 August 2014; Revised 12 October 2014; Accepted 13 October 2014; Published 11 November 2014

Academic Editor: Riccarda Granata

Copyright © 2014 Jie Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. Sowers, M. Epstein, and E. D. Frohlich, “Diabetes, hypertension, and cardiovascular disease: an update,” Hypeytension, vol. 37, no. 4, pp. 1053–1059, 2001. View at Publisher · View at Google Scholar
  2. D. R. Tomlinson, “Mitogen-activated protein kinases as glucose transducers for diabetic complications,” Diabetologia, vol. 42, no. 11, pp. 1271–1281, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Begum and L. Ragolia, “High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation,” American Journal of Physiology—Cell Physiology, vol. 278, no. 1, pp. C81–C91, 2000. View at Google Scholar · View at Scopus
  4. G. Soldatos and M. E. Cooper, “Diabetic nephropathy: important pathophysiologic mechanisms,” Diabetes Research and Clinical Practice, vol. 82, supplement 1, pp. S75–S79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Sato, H. Kawamura, M. Takemoto et al., “Halofuginone prevents extracellular matrix deposition in diabetic nephropathy,” Biochemical and Biophysical Research Communications, vol. 379, no. 2, pp. 411–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Chen, Y. Qiong, and D. G. Gardner, “A role for p38 mitogen-activated protein kinase and c-Myc in endothelin-dependent rat aortic smooth muscle cell proliferation,” Hypertension, vol. 47, no. 2, pp. 252–258, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Dai, E. Rubie, C. C. Franklin et al., “Stress-activated protein kinases bind directly to the δ domain of c-Jun in resting cells: implications for repression of c-Jun function,” Oncogene, vol. 10, no. 5, pp. 849–855, 1995. View at Google Scholar · View at Scopus
  8. M. Dorenkamp, A. Riad, S. Stiehl et al., “Protection against oxidative stress in diabetic rats: role of angiotensin AT1 receptor and beta 1-adrenoceptor antagonism,” European Journal of Pharmacology, vol. 520, no. 1–3, pp. 179–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. B. S. Cain, D. R. Meldrum, X. Meng et al., “p38 MAPK inhibition decreases TNF-α production and enhances postischemic human myocardial function,” Journal of Surgical Research, vol. 83, no. 1, pp. 7–12, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Pietersma, B. C. Tilly, M. Gaestel et al., “P38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level,” Biochemical and Biophysical Research Communications, vol. 230, no. 1, pp. 44–48, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Natarajan, S. Scott, B. Wei, K. K. V. Yerneni, and J. Nadler, “Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions,” Hypertension, vol. 33, no. 1, pp. 378–384, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Igarashi, H. Wakasaki, N. Takahara et al., “Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways,” Journal of Clinical Investigation, vol. 103, no. 2, pp. 185–195, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Dorenkamp, A. Riad, S. Stiehl et al., “Protection against oxidative stress in diabetic rats: role of angiotensin AT1 receptor and beta 1-adrenoceptor antagonism,” European Journal of Pharmacology, vol. 520, no. 1–3, pp. 179–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Jie, W. Y. Tian, P. Li et al., “The study of Beraprost sodium on inflammatory factors in diabetic rats,” Chinese Journal of Multiple Organ Diseases in the Elderly, vol. 7, no. 4, pp. 514–516, 2012. View at Google Scholar
  15. B. S. Cain, D. R. Meldrum, X. Meng et al., “p38 MAPK inhibition decreases TNF-α production and enhances postischemic human myocardial function,” Journal of Surgical Research, vol. 83, no. 1, pp. 7–12, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Communal, W. S. Colucci, and K. Singh, “p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against β-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation,” Journal of Biological Chemistry, vol. 275, no. 25, pp. 19395–19400, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. Q. Liang and J. D. Molkentin, “Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models,” Journal of Molecular and Cellular Cardiology, vol. 35, no. 12, pp. 1385–1394, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Li, D. Georgakopoulos, G. Lu et al., “p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart,” Circulation, vol. 111, no. 19, pp. 2494–2502, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Zarubin and J. Han, “Activation and signaling of the p38 MAP kinase pathway,” Cell Research, vol. 15, no. 1, pp. 11–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Adhikary, F. Chow, D. J. Nikolic-Paterson et al., “Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy,” Diabetologia, vol. 47, no. 7, pp. 1210–1222, 2004. View at Google Scholar · View at Scopus
  21. R. Komers, J. N. Lindsley, T. T. Oyama, D. M. Cohen, and S. Anderson, “Renal p38 MAP kinase activity in experimental diabetes,” Laboratory Investigation, vol. 87, no. 6, pp. 548–558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Zheng, C. Reynolds, S.-H. Jo, R. Wersto, Q. Han, and R.-P. Xiao, “Intracellular acidosis-activated p38 MAPK signaling and its essential role in cardiomyocyte hypoxic injury,” The FASEB Journal, vol. 19, no. 1, pp. 109–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Westermann, S. Rutschow, S. Van Linthout et al., “Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus,” Diabetologia, vol. 49, no. 10, pp. 2507–2513, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Riad, D. Unger, J. Du et al., “Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus,” European Journal of Pharmacology, vol. 554, no. 1, pp. 40–45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Yamaguchi, C. Inada, M. Tamura et al., “Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats,” European Journal of Pharmacology, vol. 714, no. 1–3, pp. 325–331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Ueno, H. Koike, and S. Nishio, “Beneficial effects of beraprost sodium, a stable prostacyclin analogue, in diabetic cardiomyopathy,” Journal of Cardiovascular Pharmacology, vol. 26, no. 4, pp. 603–607, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Sato, M. Kaneko, M. Tamura, and H. Kurumatani, “The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese zucker (fatty) rats,” Diabetes, vol. 59, no. 4, pp. 1092–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Y.-M. Sun, “Study of SOD and PON-1 expression in type 2 diabetes mellitus nephropathy and its clinical significance,” Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, vol. 26, no. 11, pp. 1120–1121, 2010. View at Google Scholar · View at Scopus
  29. M. Nakhjavani, A. Esteghamati, S. Nowroozi, F. Asgarani, A. Rashidi, and O. Khalilzadeh, “Type 2 diabetes mellitus duration: an independent predictor of serum malondialdehyde levels,” Singapore Medical Journal, vol. 51, no. 7, pp. 582–585, 2010. View at Google Scholar · View at Scopus
  30. R. I. Staiano, F. Granata, A. Secondo et al., “Expression and function of Na+/Ca2+ exchangers 1 and 3 in human macrophages and monocytes,” European Journal of Immunology, vol. 39, no. 5, pp. 1405–1418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. G. Kiang and K. T. Tsen, “Biology of hypoxia,” The Chinese Journal of Physiology, vol. 49, no. 5, pp. 223–233, 2006. View at Google Scholar · View at Scopus
  32. Y. Akasaka, N. Morimoto, Y. Ishikawa et al., “Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction,” Modern Pathology, vol. 19, no. 4, pp. 588–598, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Ichijo, E. Nishida, K. Irie et al., “Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways,” Science, vol. 275, no. 5296, pp. 90–94, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Pearson, F. Robinson, T. B. Gibson et al., “Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions,” Endocrine Reviews, vol. 22, no. 2, pp. 153–183, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. M. D. Sternlicht and Z. Werb, “How matrix metalloproteinases regulate cell behavior,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 463–516, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Kajiwara, Z. Luo, A. J. Belanger et al., “A hypoxic inducible factor-1 alpha hybrid enhances collateral development and reduces vascular leakage in diabetic rats,” The Journal of Gene Medicine, vol. 11, no. 5, pp. 390–400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Scorrano and S. J. Korsmeyer, “Mechanisms of cytochrome c release by proapoptotic BCL-2 family members,” Biochemical and Biophysical Research Communications, vol. 304, no. 3, pp. 437–444, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Okuno, A. Saito, T. Hayashi, and P. H. Chan, “The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia,” The Journal of Neuroscience, vol. 24, no. 36, pp. 7879–7887, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. J. F. Kurland, D. W. Voehringer, and R. E. Meyn, “The MEK/ERK pathway acts upstream of NFκB1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis,” Journal of Biological Chemistry, vol. 278, no. 34, pp. 32465–32470, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. S. L. Mehta, N. Manhas, and R. Raghubir, “Molecular targets in cerebral ischemia for developing novel therapeutics,” Brain Research Reviews, vol. 54, no. 1, pp. 34–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Rengao and L. Zaiying, Internal Medicine, People's Medical Press, Beijing, China, 6th edition, 2006.
  42. K. Sakai, K. Shibazaki, K. Kimura et al., “Brain natriuretic peptide as a predictor of cardioembolism in acute ischemic stroke patients: brain natriuretic peptide stroke prospective study,” European Neurology, vol. 69, no. 4, pp. 246–251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. D. S. Fernandez-Twinn, H. L. Blackmore, L. Siggens et al., “The programming of cardiac hypertrophy in the offspring by maternal obesity is associated with hyperinsulinemia, AKT, ERK, and mTOR activation,” Endocrinology, vol. 153, no. 12, pp. 5961–5971, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Kislinger, N. Tanji, T. Wendt et al., “Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 6, pp. 905–910, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Wondergem, E. G. Strootman, M. Frölich, J. W. H. Leer, and E. M. Noordijk, “Circulating atrial natriuretic peptide plasma levels as a marker for cardiac damage after radiotherapy,” Radiotherapy and Oncology, vol. 58, no. 3, pp. 295–301, 2001. View at Publisher · View at Google Scholar · View at Scopus